JP2013519675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013519675A5 JP2013519675A5 JP2012552978A JP2012552978A JP2013519675A5 JP 2013519675 A5 JP2013519675 A5 JP 2013519675A5 JP 2012552978 A JP2012552978 A JP 2012552978A JP 2012552978 A JP2012552978 A JP 2012552978A JP 2013519675 A5 JP2013519675 A5 JP 2013519675A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- disease
- related disorder
- pharmaceutical composition
- cns
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000010425 asbestos Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000034737 hemoglobinopathy Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 229910052895 riebeckite Inorganic materials 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30361810P | 2010-02-11 | 2010-02-11 | |
| US61/303,618 | 2010-02-11 | ||
| PCT/US2011/024269 WO2011100380A1 (en) | 2010-02-11 | 2011-02-10 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016004951A Division JP6215976B2 (ja) | 2010-02-11 | 2016-01-14 | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013519675A JP2013519675A (ja) | 2013-05-30 |
| JP2013519675A5 true JP2013519675A5 (https=) | 2014-03-27 |
Family
ID=43708752
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012552978A Withdrawn JP2013519675A (ja) | 2010-02-11 | 2011-02-10 | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
| JP2016004951A Active JP6215976B2 (ja) | 2010-02-11 | 2016-01-14 | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
| JP2016080097A Withdrawn JP2016172746A (ja) | 2010-02-11 | 2016-04-13 | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
| JP2016171451A Active JP6270944B2 (ja) | 2010-02-11 | 2016-09-02 | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
| JP2017125219A Pending JP2017200944A (ja) | 2010-02-11 | 2017-06-27 | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016004951A Active JP6215976B2 (ja) | 2010-02-11 | 2016-01-14 | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
| JP2016080097A Withdrawn JP2016172746A (ja) | 2010-02-11 | 2016-04-13 | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
| JP2016171451A Active JP6270944B2 (ja) | 2010-02-11 | 2016-09-02 | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
| JP2017125219A Pending JP2017200944A (ja) | 2010-02-11 | 2017-06-27 | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
Country Status (33)
| Country | Link |
|---|---|
| US (8) | US8518972B2 (https=) |
| EP (6) | EP2536706B1 (https=) |
| JP (5) | JP2013519675A (https=) |
| KR (2) | KR101812356B1 (https=) |
| CN (2) | CN102822165B (https=) |
| AR (1) | AR081058A1 (https=) |
| AU (1) | AU2011215877C1 (https=) |
| CA (1) | CA2787823C (https=) |
| CO (1) | CO6571916A2 (https=) |
| CR (1) | CR20120414A (https=) |
| CY (3) | CY1119177T1 (https=) |
| DK (3) | DK3202461T3 (https=) |
| EC (1) | ECSP12012098A (https=) |
| ES (5) | ES2713482T3 (https=) |
| HR (3) | HRP20171078T1 (https=) |
| HU (3) | HUE033009T2 (https=) |
| IL (2) | IL220992A (https=) |
| LT (3) | LT3202460T (https=) |
| ME (2) | ME02766B (https=) |
| MX (3) | MX337169B (https=) |
| NI (1) | NI201200132A (https=) |
| NZ (3) | NZ700054A (https=) |
| PH (2) | PH12012501607A1 (https=) |
| PL (3) | PL3202460T3 (https=) |
| PT (3) | PT2536706T (https=) |
| RS (3) | RS59275B1 (https=) |
| RU (1) | RU2567753C2 (https=) |
| SG (3) | SG10202012179RA (https=) |
| SI (3) | SI2536706T1 (https=) |
| SM (3) | SMT201900420T1 (https=) |
| TR (1) | TR201903027T4 (https=) |
| UA (2) | UA115220C2 (https=) |
| WO (1) | WO2011100380A1 (https=) |
Families Citing this family (168)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2436387B1 (en) | 2009-05-25 | 2018-07-25 | Celgene Corporation | Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex |
| EP2536706B1 (en) * | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| AU2012236655B2 (en) * | 2011-03-28 | 2016-09-22 | Deuterx, Llc, | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| CA2834535A1 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| DK2882737T3 (da) | 2012-08-09 | 2019-05-13 | Celgene Corp | Fast form af (s)-3-(4-((4-morpholinmethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin-2,6-dion hydrochlorid |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| US20140343058A1 (en) * | 2012-08-09 | 2014-11-20 | Celgene Corporation | Treatment of systemic lupus erythematosus |
| BR112015002285B1 (pt) * | 2012-08-09 | 2022-05-10 | Celgene Corporation | Uso do composto 3-(4-((4-(morfolinometil)benzil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona para tratar ou gerenciar câncer |
| ES2712652T3 (es) * | 2012-08-09 | 2019-05-14 | Celgene Corp | Procesos para la preparación de (S)-3-4-((4-(morfolinometil) bencil) oxi) -1-oxoisoindolin-2il-) piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas |
| NZ727295A (en) * | 2012-08-09 | 2018-06-29 | Celgene Corp | Treatment of immune-related and inflammatory diseases |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| MX2015003114A (es) | 2012-09-10 | 2015-07-06 | Celgene Corp | Metodos para el tratamiento de cancer de mama localmente avanzado. |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| CA2935495C (en) | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| US9695145B2 (en) | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| EP2968334A4 (en) | 2013-03-14 | 2016-08-03 | Deuterx Llc | 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES |
| AU2014240083C1 (en) | 2013-03-15 | 2019-10-24 | Celgene Corporation | Modified T lymphocytes |
| CN105358177B (zh) | 2013-04-17 | 2018-11-23 | 西格诺药品有限公司 | 包含tor激酶抑制剂和imid化合物的联合疗法用于治疗癌症 |
| UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| IL278381B2 (en) | 2013-12-06 | 2024-08-01 | Celgene Corp | Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| AU2015247817C1 (en) * | 2014-04-14 | 2022-02-10 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US10245266B2 (en) | 2014-05-19 | 2019-04-02 | Celgene Corporation | 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
| WO2015200795A1 (en) | 2014-06-27 | 2015-12-30 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases |
| CA2957225A1 (en) | 2014-08-07 | 2016-02-11 | Calithera Biosciences, Inc. | Crystal forms of glutaminase inhibitors |
| KR20170042598A (ko) | 2014-08-22 | 2017-04-19 | 셀진 코포레이션 | 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법 |
| CN111205268B (zh) * | 2014-10-30 | 2021-01-26 | 康朴生物医药技术（上海）有限公司 | 异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用 |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| SG10202106529XA (en) * | 2015-07-21 | 2021-07-29 | Immunogen Inc | Methods of preparing cytotoxic benzodiazepine derivatives |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| DK3357513T3 (da) * | 2015-09-29 | 2023-11-27 | Kangpu Biopharmaceuticals Inc | Farmaceutisk sammensætning og anvendelse deraf |
| WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| WO2017176958A1 (en) * | 2016-04-06 | 2017-10-12 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| MX384905B (es) * | 2016-04-12 | 2025-03-14 | Univ Michigan Regents | Degradadores de proteínas de bromodominio y dominioextraterminal (bet). |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| WO2018071606A1 (en) | 2016-10-11 | 2018-04-19 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| EP3532464A4 (en) | 2016-10-28 | 2020-07-08 | Icahn School of Medicine at Mount Sinai | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER |
| IL290809B2 (en) | 2016-11-01 | 2024-01-01 | Arvinas Operations Inc | Tau-protein targeting protacs and associated methods of use |
| EP4295918A3 (en) | 2016-11-02 | 2024-03-20 | Bristol-Myers Squibb Company | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
| KR102674902B1 (ko) | 2016-12-01 | 2024-06-14 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
| JP2020514252A (ja) | 2016-12-08 | 2020-05-21 | アイカーン スクール オブ メディスン アット マウント シナイ | Ｃｄｋ４／６媒介性がんを治療するための組成物および方法 |
| US10933059B2 (en) * | 2016-12-16 | 2021-03-02 | Kangpu Biopharmaceuticals. Ltd. | Combination, application thereof and treatment method |
| MX2019007646A (es) | 2016-12-23 | 2019-09-06 | Arvinas Operations Inc | Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso. |
| CN117510491A (zh) | 2016-12-23 | 2024-02-06 | 阿尔维纳斯运营股份有限公司 | 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法 |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| AU2018211975B2 (en) | 2017-01-26 | 2022-05-26 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| US10434095B2 (en) | 2017-01-27 | 2019-10-08 | Celgene Corporation | 3-(1-oxo-4-((4-((3-oxomorpholino)methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof |
| BR112019015484A2 (pt) | 2017-01-31 | 2020-04-28 | Arvinas Operations Inc | ligantes de cereblon e compostos bifuncionais compreendendo os mesmos |
| WO2018144832A1 (en) | 2017-02-03 | 2018-08-09 | Celgene Corporation | Methods for measuring small molecule affinity to cereblon |
| AU2017202864B2 (en) * | 2017-02-13 | 2020-04-23 | Kangpu Biopharmaceuticals, Ltd. | Combination treating prostate cancer, pharmaceutical composition and treatment method |
| CN108929307A (zh) * | 2017-05-22 | 2018-12-04 | 苏州偶领生物医药有限公司 | 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途 |
| TWI791552B (zh) * | 2017-07-10 | 2023-02-11 | 美商西建公司 | 抗增生化合物及其使用方法 |
| EP3672939A1 (en) | 2017-08-21 | 2020-07-01 | Celgene Corporation | Processes for preparation of (s)-tert-butyl 4,5-diamino-5-oxopentanoate |
| US10513515B2 (en) * | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| MX2020003242A (es) | 2017-09-22 | 2020-09-18 | Jubilant Epipad LLC | Compuestos heterociclicos como inhibidores de pad. |
| AU2018352142B2 (en) | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
| KR20200085836A (ko) | 2017-11-06 | 2020-07-15 | 주빌런트 프로델 엘엘씨 | Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체 |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| BR112020010322A2 (pt) | 2017-11-24 | 2020-11-17 | Jubilant Episcribe Llc | composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2019146773A1 (ja) | 2018-01-25 | 2019-08-01 | 株式会社フジモト・コーポレーション | チオフェン誘導体およびその用途 |
| US11220515B2 (en) | 2018-01-26 | 2022-01-11 | Yale University | Imide-based modulators of proteolysis and associated methods of use |
| KR20200123155A (ko) | 2018-02-21 | 2020-10-28 | 셀진 코포레이션 | Bcma-결합 항체 및 이의 용도 |
| CA3092677A1 (en) | 2018-03-06 | 2019-09-12 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (akt) degradation / disruption compounds and methods of use |
| SG11202008950PA (en) | 2018-03-13 | 2020-10-29 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| KR20210006356A (ko) | 2018-04-04 | 2021-01-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해 조절제 및 연관된 사용 방법 |
| CN118344338A (zh) * | 2018-04-23 | 2024-07-16 | 细胞基因公司 | 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途 |
| CA3104298A1 (en) | 2018-06-21 | 2019-12-26 | Icahn School Of Medicine At Mount Sinai | Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use |
| SG11202011818YA (en) | 2018-06-29 | 2020-12-30 | Hoffmann La Roche | Compounds |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| DK3820573T3 (da) * | 2018-07-10 | 2023-10-23 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme |
| AU2019309894A1 (en) | 2018-07-27 | 2021-01-28 | Biotheryx, Inc. | Bifunctional compounds as CDK modulators |
| EP3841100A1 (en) | 2018-08-20 | 2021-06-30 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
| WO2020048546A1 (zh) * | 2018-09-07 | 2020-03-12 | 南京明德新药研发有限公司 | 三环取代哌啶二酮类化合物 |
| KR102672549B1 (ko) * | 2018-09-30 | 2024-06-10 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 이소인돌린계 화합물, 이의 제조 방법, 약학 조성물 및 용도 |
| AU2019351811B2 (en) | 2018-10-01 | 2025-01-02 | Celgene Corporation | Combination therapy for the treatment of cancer |
| WO2020097403A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
| JP7623943B2 (ja) | 2018-11-30 | 2025-01-29 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| EP3891128A4 (en) * | 2018-12-05 | 2022-08-17 | Vividion Therapeutics, Inc. | SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEOSUBSTRATE RECRUITMENT |
| EP3896062A4 (en) | 2018-12-06 | 2022-06-15 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | ISOINDOLINE COMPOUND, METHOD FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE OF ISOINDOLINE COMPOUND |
| WO2020146440A1 (en) | 2019-01-09 | 2020-07-16 | Celgene Corporation | Antiproliferative compounds and second active agents for use in treating multiple myeloma |
| AU2020206692B2 (en) | 2019-01-09 | 2025-03-27 | Celgene Corporation | Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
| RS67646B1 (sr) | 2019-01-09 | 2026-02-27 | Celgene Corp | Čvrsti oblici koji obuhvataju (s)-4-(4-(4-(((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-4-il)oksi)metil) benzil)piperazin-1-il)-3-fluorobenzonitril i soli istog, kao i kompozicije koje obuhvataju i metode korišćenja istih |
| EP3932922A4 (en) | 2019-02-25 | 2022-05-11 | ShanghaiTech University | SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE |
| AR119715A1 (es) * | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| CN118908962A (zh) | 2019-05-06 | 2024-11-08 | 西奈山伊坎医学院 | 作为hpk1的降解剂的异双功能化合物 |
| BR112021026517A2 (pt) | 2019-06-28 | 2022-05-10 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN119954801A (zh) | 2019-07-17 | 2025-05-09 | 阿尔维纳斯运营股份有限公司 | Tau蛋白靶向化合物及相关使用方法 |
| WO2021023233A1 (zh) | 2019-08-05 | 2021-02-11 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| IL320609A (en) | 2019-08-26 | 2025-07-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| CN115397821B (zh) | 2019-10-17 | 2024-09-03 | 阿尔维纳斯运营股份有限公司 | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 |
| JP7676375B2 (ja) | 2019-10-21 | 2025-05-14 | セルジーン コーポレーション | （ｓ）－２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンおよびその塩を含む固形体、並びにそれを含む組成物およびそれを使用する方法 |
| AU2020377930A1 (en) | 2019-11-05 | 2022-05-19 | Bristol-Myers Squibb Company | Uses of anti-BCMA chimeric antigen receptors |
| IL292667B1 (en) | 2019-11-07 | 2026-02-01 | Juno Therapeutics Inc | Combination of T-cell therapy and (s)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-l-oxo-3,l-dihydro-isoindol-2-yl]-piperidine-6,2-dione |
| WO2021105335A1 (en) | 2019-11-27 | 2021-06-03 | Captor Therapeutics S.A. | Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof |
| AU2020392427B2 (en) | 2019-11-27 | 2024-03-07 | Captor Therapeutics S.A. | Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof |
| JP2023505150A (ja) | 2019-12-02 | 2023-02-08 | セルジーン コーポレーション | がんの処置のための治療法 |
| US12551564B2 (en) | 2019-12-10 | 2026-02-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| FI3835298T3 (fi) * | 2019-12-12 | 2024-07-29 | Accutar Biotechnology Inc | Uusia kromaanijohdannaisia, joilla on estrogeenireseptoria hajottava vaikutus, ja niiden käyttötapoja |
| WO2021127190A1 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| JP7682181B2 (ja) * | 2019-12-18 | 2025-05-23 | ノバルティス アーゲー | ３－（５－メトキシ－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| CA3165168A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| WO2021133886A1 (en) | 2019-12-23 | 2021-07-01 | Accutar Biotechnology | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer |
| US20230114674A1 (en) * | 2020-01-20 | 2023-04-13 | Kangpu Biopharmaceuticals, Ltd. | Isoindoline derivative, and pharmaceutical composition and use thereof |
| CA3169011A1 (en) * | 2020-02-25 | 2021-09-02 | Xiaobao Yang | Glutarimide skeleton-based compounds and uses thereof |
| US11897930B2 (en) | 2020-04-28 | 2024-02-13 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| JP2023524068A (ja) | 2020-04-30 | 2023-06-08 | ブリストル－マイヤーズ スクイブ カンパニー | サイトカイン関連有害事象を治療する方法 |
| CN115996918A (zh) | 2020-05-09 | 2023-04-21 | 阿尔维纳斯运营股份有限公司 | 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型 |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| CN115916191A (zh) | 2020-06-25 | 2023-04-04 | 新基公司 | 用组合疗法治疗癌症的方法 |
| CN113896711A (zh) * | 2020-07-06 | 2022-01-07 | 北京诺诚健华医药科技有限公司 | 杂环类免疫调节剂 |
| EP4183781A4 (en) * | 2020-07-20 | 2024-01-03 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Sulfur-containing isoindoline derivative, and preparation method therefor and medical use thereof |
| KR20230048373A (ko) | 2020-08-03 | 2023-04-11 | 캡터 테라퓨틱스 에스.에이. | 저분자량 단백질 분해제 및 이의 응용 |
| JP7834721B2 (ja) | 2020-08-28 | 2026-03-24 | アルビナス・オペレーションズ・インコーポレイテッド | 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法 |
| US20230310478A1 (en) * | 2020-09-02 | 2023-10-05 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Methods and compositions for the treatment of pulmonary hypertension and cancer |
| WO2022053652A1 (en) | 2020-09-11 | 2022-03-17 | Engmab Sàrl | Combination therapy for cancer |
| AR123492A1 (es) | 2020-09-14 | 2022-12-07 | Arvinas Operations Inc | Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno |
| WO2022066580A1 (en) * | 2020-09-23 | 2022-03-31 | Kinnate Biopharma Inc. | Raf degrading compounds |
| AR123650A1 (es) | 2020-10-02 | 2022-12-28 | Celgene Corp | Métodos para el tratamiento del lupus eritematoso sistémico y el uso de biomarcadores como un predictor de sensibilidad clínica a terapias |
| EP4241278A2 (en) | 2020-11-04 | 2023-09-13 | Celgene Corporation | Car t cell therapy in patients who have had prior anti-cancer alkylator therapy |
| CN112174976A (zh) * | 2020-11-19 | 2021-01-05 | 江西中医药大学 | 从水芹菜中分离的二苯并呋喃型木脂素及其方法和在抗痛风性关节炎上的用途 |
| PH12023500015A1 (en) | 2020-12-30 | 2024-03-11 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2022146151A1 (en) | 2020-12-30 | 2022-07-07 | Captor Therapeutics S.A. | Novel compounds which bind to cereblon, and methods of use thereof |
| WO2022148358A1 (zh) * | 2021-01-05 | 2022-07-14 | 江苏恒瑞医药股份有限公司 | 稠杂环基取代的环己二酰亚胺衍生物、其制备方法及其在医药上的应用 |
| JP2024504932A (ja) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス， インコーポレイテッド | イソインドリノン化合物 |
| CN116867494A (zh) | 2021-02-15 | 2023-10-10 | 凯麦拉医疗公司 | Irak4降解剂和其用途 |
| WO2022174268A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| UY39671A (es) | 2021-03-15 | 2022-10-31 | Novartis Ag | Derivados de pirazolopiridina y sus usos. |
| US20240217968A1 (en) * | 2021-03-31 | 2024-07-04 | Duke Street Bio Limited | Pharmaceutical compound |
| CN117279910A (zh) | 2021-04-16 | 2023-12-22 | 阿尔维纳斯运营股份有限公司 | Bcl6蛋白水解的调节剂和其相关使用方法 |
| WO2022255889A1 (en) | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
| WO2022255890A1 (en) | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
| PY2243958A (es) | 2021-06-03 | 2023-01-20 | Novartis Ag | Derivados de 3–(5–oxi)–1–oxoisoindolin–2–il)piperidina–2,6–diona y sus usos |
| CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
| WO2023025136A1 (zh) * | 2021-08-27 | 2023-03-02 | 杭州格博生物医药有限公司 | 异吲哚啉酮化合物及其用途 |
| WO2023034411A1 (en) * | 2021-09-01 | 2023-03-09 | Oerth Bio Llc | Compositions and methods for targeted degradation of proteins in a plant cell |
| US12187744B2 (en) | 2021-10-29 | 2025-01-07 | Kymera Therapeutics, Inc. | IRAK4 degraders and synthesis thereof |
| WO2023138647A1 (zh) * | 2022-01-19 | 2023-07-27 | 江苏恒瑞医药股份有限公司 | 一种含硫异吲哚啉类衍生物的晶型 |
| CN116462660A (zh) * | 2022-01-19 | 2023-07-21 | 江苏恒瑞医药股份有限公司 | 一种异喹啉酮类化合物的盐及其晶型 |
| EP4472967A4 (en) | 2022-01-31 | 2026-04-15 | Kymera Therapeutics Inc | Iraqi Degradation Agents and Their Uses |
| US20250295771A1 (en) | 2022-05-11 | 2025-09-25 | Celgene Corporation | Methods and uses related to t cell therapy and production of same |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| CN115160211B (zh) * | 2022-06-23 | 2023-11-03 | 温州大学 | 一种异吲哚啉酮类化合物的绿色合成方法 |
| WO2023246944A1 (zh) * | 2022-06-24 | 2023-12-28 | 中国科学院上海药物研究所 | 一类取代的4-氨基异吲哚啉类化合物、其制备方法、药物组合物及应用 |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| WO2024064646A1 (en) | 2022-09-20 | 2024-03-28 | Celgene Corporation | Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same |
| WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
| EP4619399A1 (en) | 2022-11-16 | 2025-09-24 | Basf Se | New substituted tetrahydrobenzoxazepine |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
| WO2024167423A1 (en) | 2023-02-07 | 2024-08-15 | Captor Therapeutics S.A. | Gspt1 degrader compounds |
| WO2025042742A1 (en) | 2023-08-18 | 2025-02-27 | Bristol-Myers Squibb Company | Compositions comprising antibodies that bind bcma and cd3 and methods of treatment |
| WO2025076472A1 (en) | 2023-10-06 | 2025-04-10 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| TW202532072A (zh) | 2023-12-08 | 2025-08-16 | 美商西建公司 | 治療多發性骨髓瘤之療法 |
| US12496301B2 (en) | 2023-12-08 | 2025-12-16 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
| WO2025195464A1 (zh) * | 2024-03-21 | 2025-09-25 | 上海惠康济民生物医药技术有限公司 | 取代的异吲哚啉类化合物、制备方法、药物组合物及应用 |
| WO2026022712A1 (en) | 2024-07-23 | 2026-01-29 | Sanofi | Cereblon ligase modulator and bcma nk cell engager combination therapy |
| US12565492B2 (en) | 2024-08-09 | 2026-03-03 | Triana Biomedicines, Inc. | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4421865A (en) * | 1981-06-08 | 1983-12-20 | Standard Oil Company (Sohio) | Selective hydrogen-deuterium interchange using ion exchange resins |
| US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5149820A (en) * | 1987-03-11 | 1992-09-22 | Norsk Hydro A.S. | Deuterated compounds |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| WO1992014455A1 (en) * | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| WO1994007498A1 (fr) * | 1992-10-07 | 1994-04-14 | Sumitomo Pharmaceuticals Company, Limited | Composition pharmaceutique utilisee pour inhiber la production des facteurs de necrose tumorale |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| WO1995003807A1 (en) | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
| AU6242096A (en) | 1995-06-27 | 1997-01-30 | Takeda Chemical Industries Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| NZ333903A (en) | 1996-07-24 | 2000-02-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1oxoisoindolines and method of reducing TNF-alpha levels in a mammal |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| DE69730093T2 (de) | 1996-10-31 | 2006-07-20 | Takeda Pharmaceutical Co. Ltd. | Zubereitung mit verzögerter Freisetzung |
| WO1998027980A2 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| EP1064277B1 (en) | 1998-03-16 | 2005-06-15 | Celgene Corporation | 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
| US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| DE60117486T2 (de) | 2000-08-23 | 2006-11-16 | General Electric Co. | Spritzgegossene Keramik-Metallhalogenidbogenröhre mit einem nicht-konischen Ende |
| US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| CN1511420A (zh) | 2001-11-09 | 2004-07-07 | ���µ�����ҵ��ʽ���� | 运动图像编码方法和装置 |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| CN102342938B (zh) | 2002-05-17 | 2014-08-20 | 细胞基因公司 | 用于治疗和控制实体瘤的方法及组合物 |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| CN1867331B (zh) | 2003-09-17 | 2010-05-26 | 美国政府健康及人类服务部 | 作为TNF-α调节剂的沙利度胺类似物 |
| US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| KR20120039065A (ko) | 2003-12-02 | 2012-04-24 | 셀진 코포레이션 | 혈색소병증 및 빈혈의 치료 및 관리를 위한 방법및 조성물 |
| US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| BRPI0509019A (pt) | 2004-03-22 | 2007-08-07 | Celgene Corp | métodos para tratar, prevenir ou controlar um distúrbio ou doença de pele, para tratar, prevenir ou controlar ceratose senil e para tratar ou controlar ceratose, composição farmacêutica, forma de dosagem unitária individual, e, kit |
| US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| US20050239842A1 (en) | 2004-04-23 | 2005-10-27 | Zeldis Jerome B | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
| CA2565447A1 (en) | 2004-05-05 | 2005-12-01 | Celgene Corporation | Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases |
| ATE478864T1 (de) * | 2004-07-16 | 2010-09-15 | Schering Corp | Hydantoinderivate zur behandlung von entzündlichen erkrankungen |
| US7405237B2 (en) | 2004-07-28 | 2008-07-29 | Celgene Corporation | Isoindoline compounds and methods of their use |
| US7244759B2 (en) * | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
| BRPI0514865A (pt) | 2004-09-03 | 2008-06-24 | Celgene Corp | processo para preparar um composto |
| CN101098694A (zh) | 2004-11-12 | 2008-01-02 | 细胞基因公司 | 使用免疫调节化合物治疗和控制寄生性疾病的方法和组合物 |
| JP2008520731A (ja) | 2004-11-23 | 2008-06-19 | セルジーン・コーポレーション | 中枢神経系傷害を治療及び管理するための、免疫調節性化合物を使用した方法及び組成物 |
| BRPI0518793A2 (pt) | 2004-12-01 | 2008-12-09 | Celgene Corp | mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica |
| HRP20130102T1 (hr) | 2005-06-30 | 2013-03-31 | Celgene Corporation | Postupak dobivanja spojeva 4-amino-2-(2,6-dioksopiperidin-3-il)izoindolin-1,3-diona |
| KR20080042158A (ko) * | 2005-08-31 | 2008-05-14 | 셀진 코포레이션 | 이소인돌-이미드 화합물과 이를 포함하는 조성물 및 이를이용한 방법 |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| PL2076260T3 (pl) | 2006-09-15 | 2011-08-31 | Celgene Corp | Związki N-metyloaminometylo-izoindolu, kompozycje zawierające te związki, oraz metody ich stosowania |
| WO2008057196A2 (en) | 2006-10-19 | 2008-05-15 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases |
| KR101791757B1 (ko) * | 2007-03-20 | 2017-10-30 | 셀진 코포레이션 | 4'-ｏ-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법 |
| EP2536706B1 (en) * | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| WO2012027065A2 (en) | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| US20120302605A1 (en) | 2010-11-18 | 2012-11-29 | Deuteria Pharmaceuticals, Llc | 3-deutero-pomalidomide |
| WO2012079022A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| AU2012236655B2 (en) | 2011-03-28 | 2016-09-22 | Deuterx, Llc, | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| DK2882737T3 (da) | 2012-08-09 | 2019-05-13 | Celgene Corp | Fast form af (s)-3-(4-((4-morpholinmethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin-2,6-dion hydrochlorid |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| ES2712652T3 (es) | 2012-08-09 | 2019-05-14 | Celgene Corp | Procesos para la preparación de (S)-3-4-((4-(morfolinometil) bencil) oxi) -1-oxoisoindolin-2il-) piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas |
| US20140343058A1 (en) | 2012-08-09 | 2014-11-20 | Celgene Corporation | Treatment of systemic lupus erythematosus |
| NZ727295A (en) | 2012-08-09 | 2018-06-29 | Celgene Corp | Treatment of immune-related and inflammatory diseases |
| BR112015002285B1 (pt) | 2012-08-09 | 2022-05-10 | Celgene Corporation | Uso do composto 3-(4-((4-(morfolinometil)benzil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona para tratar ou gerenciar câncer |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| MX2015003114A (es) | 2012-09-10 | 2015-07-06 | Celgene Corp | Metodos para el tratamiento de cancer de mama localmente avanzado. |
| US9695145B2 (en) | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| CN105050624A (zh) | 2013-03-14 | 2015-11-11 | 细胞基因公司 | 利用阿普斯特来治疗银屑病关节炎的方法 |
| CN105358177B (zh) | 2013-04-17 | 2018-11-23 | 西格诺药品有限公司 | 包含tor激酶抑制剂和imid化合物的联合疗法用于治疗癌症 |
| UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| IL278381B2 (en) | 2013-12-06 | 2024-08-01 | Celgene Corp | Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| US10245266B2 (en) | 2014-05-19 | 2019-04-02 | Celgene Corporation | 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
| WO2015200795A1 (en) | 2014-06-27 | 2015-12-30 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases |
| US10092541B2 (en) | 2014-08-15 | 2018-10-09 | Celgene Corporation | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
| WO2016060702A1 (en) | 2014-10-13 | 2016-04-21 | Celgene Corporaton | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| CN111205268B (zh) | 2014-10-30 | 2021-01-26 | 康朴生物医药技术（上海）有限公司 | 异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用 |
| US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
-
2011
- 2011-02-10 EP EP11704156.6A patent/EP2536706B1/en active Active
- 2011-02-10 CN CN201180018485.1A patent/CN102822165B/zh active Active
- 2011-02-10 PL PL17157170T patent/PL3202460T3/pl unknown
- 2011-02-10 SI SI201131241T patent/SI2536706T1/sl unknown
- 2011-02-10 ES ES17157178T patent/ES2713482T3/es active Active
- 2011-02-10 HU HUE11704156A patent/HUE033009T2/en unknown
- 2011-02-10 HR HRP20171078TT patent/HRP20171078T1/hr unknown
- 2011-02-10 NZ NZ700054A patent/NZ700054A/en unknown
- 2011-02-10 ES ES19178064T patent/ES2956743T3/es active Active
- 2011-02-10 RU RU2012138709/04A patent/RU2567753C2/ru active
- 2011-02-10 CN CN201510039358.XA patent/CN104693193B/zh active Active
- 2011-02-10 CA CA2787823A patent/CA2787823C/en active Active
- 2011-02-10 SI SI201131754T patent/SI3202460T1/sl unknown
- 2011-02-10 EP EP23192393.9A patent/EP4289838A3/en active Pending
- 2011-02-10 TR TR2019/03027T patent/TR201903027T4/tr unknown
- 2011-02-10 ES ES11704156.6T patent/ES2638517T3/es active Active
- 2011-02-10 HU HUE17157170 patent/HUE044652T2/hu unknown
- 2011-02-10 LT LTEP17157170.6T patent/LT3202460T/lt unknown
- 2011-02-10 WO PCT/US2011/024269 patent/WO2011100380A1/en not_active Ceased
- 2011-02-10 US US13/025,105 patent/US8518972B2/en active Active
- 2011-02-10 ME MEP-2017-136A patent/ME02766B/me unknown
- 2011-02-10 PT PT117041566T patent/PT2536706T/pt unknown
- 2011-02-10 UA UAA201210643A patent/UA115220C2/uk unknown
- 2011-02-10 EP EP16166423.0A patent/EP3106460B1/en active Active
- 2011-02-10 ME MEP-2019-195A patent/ME03441B/me unknown
- 2011-02-10 SG SG10202012179RA patent/SG10202012179RA/en unknown
- 2011-02-10 EP EP17157178.9A patent/EP3202461B1/en active Active
- 2011-02-10 HU HUE17157178A patent/HUE042011T2/hu unknown
- 2011-02-10 EP EP19178064.2A patent/EP3599236B1/en active Active
- 2011-02-10 PH PH1/2012/501607A patent/PH12012501607A1/en unknown
- 2011-02-10 KR KR1020127023615A patent/KR101812356B1/ko active Active
- 2011-02-10 JP JP2012552978A patent/JP2013519675A/ja not_active Withdrawn
- 2011-02-10 RS RSP20190965 patent/RS59275B1/sr unknown
- 2011-02-10 PL PL17157178T patent/PL3202461T3/pl unknown
- 2011-02-10 MX MX2013011071A patent/MX337169B/es unknown
- 2011-02-10 ES ES16166423T patent/ES2730763T3/es active Active
- 2011-02-10 AU AU2011215877A patent/AU2011215877C1/en active Active
- 2011-02-10 RS RS20170700A patent/RS56232B1/sr unknown
- 2011-02-10 SG SG10201501062SA patent/SG10201501062SA/en unknown
- 2011-02-10 ES ES17157170T patent/ES2738776T3/es active Active
- 2011-02-10 MX MX2016001880A patent/MX367522B/es unknown
- 2011-02-10 SM SM20190420T patent/SMT201900420T1/it unknown
- 2011-02-10 KR KR1020177036343A patent/KR101931468B1/ko active Active
- 2011-02-10 DK DK17157178.9T patent/DK3202461T3/en active
- 2011-02-10 MX MX2012009237A patent/MX2012009237A/es active IP Right Grant
- 2011-02-10 SM SM20190155T patent/SMT201900155T1/it unknown
- 2011-02-10 NZ NZ717149A patent/NZ717149A/en unknown
- 2011-02-10 LT LTEP11704156.6T patent/LT2536706T/lt unknown
- 2011-02-10 RS RS20190249A patent/RS58523B1/sr unknown
- 2011-02-10 SI SI201131680T patent/SI3202461T1/sl unknown
- 2011-02-10 PT PT17157170T patent/PT3202460T/pt unknown
- 2011-02-10 DK DK11704156.6T patent/DK2536706T3/en active
- 2011-02-10 PT PT17157178T patent/PT3202461T/pt unknown
- 2011-02-10 NZ NZ601289A patent/NZ601289A/en unknown
- 2011-02-10 LT LTEP17157178.9T patent/LT3202461T/lt unknown
- 2011-02-10 SG SG2012059259A patent/SG183257A1/en unknown
- 2011-02-10 SM SM20170360T patent/SMT201700360T1/it unknown
- 2011-02-10 DK DK17157170.6T patent/DK3202460T3/da active
- 2011-02-10 UA UAA201601384A patent/UA114856C2/uk unknown
- 2011-02-10 PL PL11704156T patent/PL2536706T3/pl unknown
- 2011-02-10 EP EP17157170.6A patent/EP3202460B1/en active Active
- 2011-02-11 AR ARP110100436A patent/AR081058A1/es active IP Right Grant
-
2012
- 2012-07-17 IL IL220992A patent/IL220992A/en active IP Right Grant
- 2012-08-09 CR CR20120414A patent/CR20120414A/es unknown
- 2012-08-09 NI NI201200132A patent/NI201200132A/es unknown
- 2012-08-09 EC ECSP12012098 patent/ECSP12012098A/es unknown
- 2012-08-10 CO CO12135141A patent/CO6571916A2/es active IP Right Grant
-
2013
- 2013-07-26 US US13/952,386 patent/US9309219B2/en active Active
-
2014
- 2014-05-14 PH PH12014501082A patent/PH12014501082A1/en unknown
-
2016
- 2016-01-14 JP JP2016004951A patent/JP6215976B2/ja active Active
- 2016-02-10 US US15/040,980 patent/US9822094B2/en active Active
- 2016-02-10 US US15/040,971 patent/US9828361B2/en active Active
- 2016-04-13 JP JP2016080097A patent/JP2016172746A/ja not_active Withdrawn
- 2016-09-02 JP JP2016171451A patent/JP6270944B2/ja active Active
- 2016-11-08 IL IL248843A patent/IL248843B/en active IP Right Grant
-
2017
- 2017-06-27 JP JP2017125219A patent/JP2017200944A/ja active Pending
- 2017-07-18 CY CY20171100759T patent/CY1119177T1/el unknown
- 2017-10-17 US US15/786,334 patent/US10189814B2/en active Active
-
2018
- 2018-11-19 US US16/195,550 patent/US10669257B2/en active Active
-
2019
- 2019-02-22 CY CY20191100227T patent/CY1121729T1/el unknown
- 2019-02-26 HR HRP20190368TT patent/HRP20190368T1/hr unknown
- 2019-07-19 HR HRP20191312TT patent/HRP20191312T1/hr unknown
- 2019-08-02 CY CY20191100823T patent/CY1121858T1/el unknown
-
2020
- 2020-03-31 US US16/836,832 patent/US11414399B2/en active Active
-
2022
- 2022-07-18 US US17/867,294 patent/US20220411402A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013519675A5 (https=) | ||
| JP2010504973A5 (https=) | ||
| JP2009506117A5 (https=) | ||
| CY1120049T1 (el) | (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| JP2014511891A5 (https=) | ||
| JP2013014622A5 (https=) | ||
| JP2018021046A5 (https=) | ||
| JP2014507446A5 (https=) | ||
| JP2010502627A5 (https=) | ||
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| JP2014511892A5 (https=) | ||
| EA201401150A1 (ru) | Аминоиндолилзамещенные имидазолпиримидины и их применение в качестве лекарственных средств | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| JP2016510326A5 (https=) | ||
| JP2017520613A5 (https=) | ||
| ME02841B (me) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| JP2016523260A5 (https=) | ||
| JP2016522254A5 (https=) | ||
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| JP2015516419A5 (https=) | ||
| JP2016537338A5 (https=) | ||
| EA201692298A1 (ru) | Производные карбоксамидов | |
| JP2013515073A5 (https=) | ||
| JP2017513944A5 (https=) |